The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

Autor: Guy Young, Doris Quon, Janna M. Journeycake, Ismail Haroon Mitha, Thomas A. Wilkinson, Ahmad Al-Sabbagh, Johnny Mahlangu, Alok Srivastava, Philippe de Moerloose, Giancarlo Castaman, Craig M. Kessler, Kateryna V. Vilchevska, Michael Recht, Cédric Hermans, W. Allan Alexander, Michael U. Callaghan, J.-F. Schved, Santiago Bonanad Boix, James V. Luck, Oleksandra Stasyshyn, Wolfgang Miesbach, Robert F. Sidonio, Michael Wang, Amy D. Shapiro, Miguel A. Escobar, Claude Negrier, Jonathan M. Ducore, Christopher Macie, Daniel Bonzo, Cindy A. Leissinger
Přispěvatelé: UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - (SLuc) Service d'hématologie
Rok vydání: 2021
Předmět:
Zdroj: HAEMOPHILIA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Haemophilia, Vol. 27, no. 6, p. 921-931 (2021)
ISSN: 1365-2516
1351-8216
DOI: 10.1111/hae.14419
Popis: Introduction Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in haemophilia A or B patients with inhibitors (≥12 years of age). We describe here the EB safety profile from the three prospective Phase 3 clinical trials performed to date. Aim To assess EB safety, immunogenicity and thrombotic potential in children and adults who received EB for treatment of bleeding and perioperative care. Methods Using a randomized crossover design, 27 subjects in PERSEPT 1 (12-54 years) and 25 subjects in PERSEPT 2 (1-11 years) treated bleeding episodes with 75 or 225 μg/kg EB initially followed by 75 μg/kg dosing at predefined intervals as determined by clinical response. Twelve PERSEPT 3 subjects (2-56 years) received an initial preoperative infusion of 75 μg/kg (minor procedures) or 200 μg/kg EB (major surgeries) with subsequent 75 μg/kg doses administered intraoperatively and post-operatively as indicated. Descriptive statistics were used for data analyses. Results Sixty subjects who received 3388 EB doses in three trials were evaluated. EB was well tolerated, with no allergic, hypersensitivity, anaphylactic or thrombotic events reported and no neutralizing anti-EB antibodies detected. A death occurred during PERSEPT 3 and was determined to be unlikely related to EB treatment by the data monitoring committee. Conclusion Results from all three Phase 3 trials establish an excellent safety profile of EB in haemophilia A or B patients with inhibitors for treatment of bleeding and perioperative use.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje